Abstract
To investigate the combined effect of aliskiren, a renin inhibitor, and AVE 0991, a Mas-receptor agonist, in experimental hypertension (HT) in rats. HT was produced by administration of deoxycorticosterone acetate (DOCA) and mean arterial blood pressure (MABP) was assessed by tail-cuff method. Treatments were started from 4th week onwards and were continued for 9 days. A significant increase in MABP was noted after 1 week in DOCA control rats, as compared with the base line value. A stable HT developed after 4 weeks of DOCA administration. Treatments with aliskiren and AVE 0991 alone, dose-dependently decreased MABP in DOCA-treated rats. Further, combination of low doses of aliskiren and AVE 0991 significantly reduced MABP, as compared with DOCA control rats and with either drug alone in low doses. It may be concluded that treatment with aliskiren produced down-regulation of both harmful Ang II–AT1-receptor and survival Ang(1–7)/Mas-receptor axis of RAAS. Treatment with combination of low doses of aliskiren and AVE 0991, for the first time, has been shown to produce synergistic blood pressure lowering effect. Therefore, combination of renin inhibitor with Mas-receptor agonist may prove beneficial for the treatment of hypertensive patients.
Similar content being viewed by others
References
Cheung BM, Ong KL, Man YB, Lam KS, Lau CP (2006) Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001–2002. J Clin Hypertens 2:93–98
Pierdomenico SD, Di Nicola M, Esposito AL et al (2009) Prognostic value of different indices of blood pressure variability in hypertensive patients. Am J Hypertens 22:842–847
Schmieder RE, Hilgers KF, Schlaich MP et al (2007) Renin–angiotensin system and cardiovascular risk. Lancet 369:1208–1219
Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153
Israili ZH (2000) Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14:S73–S86
Chappell MC, Iyer SN, Diz DI, Ferrario CM (1998) Antihypertensive effects of angiotensin-(1–7). Braz J Med Biol Res 31:1205–1212
Roks AJM, van Geel PP, Pinto YM et al (1999) Angiotensin-(1–7) is a modulator of the human rennin–angiotensin system. Hypertension 34:296–301
Collister JP, Hendel MD (2003) The role of Ang-(1–7) in mediating the chronic hypotensive effects of losartan in normal rats. J Renin Angiotensin Aldosterone Syst 4:176–179
Donoghue M, Hsieh F, Baronas E et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238–33243
Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA (1996) Angiotensin-(1–7) inhibits vascular smooth muscle cells growth. Hypertension 28:104–108
Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI (1997) Counter-regulatory actions of angiotensin-(1–7). Hypertension 30:535–541
Singh K, Singh T, Sharma PL (2011) Beneficial effect of angiotensin (1–7) in diabetic rats with cardiomyopathy. Ther Adv Cardiovasc Dis 5:159–167
Singh T, Singh K, Sharma PL (2010) Ameliorative potential of angiotensin (1–7)/Mas receptor axis in streptozotocin-induced diabetic nephropathy in the rat. Meth Find Exp Clin Pharmacol 32:19–25
Singh K, Sharma K, Singh M, Sharma PL (2012) Possible mechanism of cardio-reno protective effects of AVE0991, a nonpeptide Mas-receptor agonist in diabetic rats. J Renin Angiotensin Aldosterione Syst 13:334–340
Wiemer G, Dobrucki LW, Louka FR, Malinski T, Heitsch H (2002) AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1–7) on the endothelium. Hypertension 40:847–852
Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA (2005) The endothelium-dependent vasodilator effect of the nonpeptide Ang(1–7) mimic AVE 0991 is abolished in the aorta of Mas-knockout mice. J Cardiovasc Pharmacol 46:274–279
Sealey JE, Laragh JH (2007) Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20:587–597
Jensen C, Herold P, Brunner HR (2008) Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 7:310–399
Pilz B, Shagdarsuren E, Wellner M et al (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569–576
Takator LK, Ogura T, Ota Z (1991) Computerized approach using autoradiography to quantify atrial natriuretic peptide receptors in the DOCA–salt hypertensive rat kidney. Regul Pept 35:115–125
Montezano ACI, Callera GE, Mota AL et al (2005) Endothelin-1 contributes to the sexual differences in renal damage in DOCA–salt rats. Peptides 26:1454–1462
Cordellini S (1999) Endothelial dysfunction in DOCA–salt hypertension possible involvement of prostaglandin endoperoxides. Gen Pharmacol 32:315–320
Lastra G, Habibi J, Whaley-Connell AT et al (2009) Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue rennin overexpression. Endocrinology 150:2561–2568
Benter IF, Yousif MHM, Anim JT, Cojocel C, Diz DI (2006) Angiotensin-(1–7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with l-NAME. Am J Physiol Heart Circ Physiol 290:H684–H691
Young M, Head G, Funder J (1995) Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269:E657–E662
Dobrzynski E, Wang C, Chao J, Chao L (2000) Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate–salt hypertensive rats. Hypertension 36:995–1001
Fowler JD, Krueth SB, Bernlohr DA, Katz SA (2009) Renin dynamics in adipose tissue: adipose tissue control of local renin concentrations. Am J Physiol Endocrinol Metab 296:E343–E350
Tank JE, Moe OW, Star RA, Henrich WL (1996) Differential regulation of rat glomerular and proximal tubular renin mRNA following uninephrectomy. Am J Physiol 270:F776–F783
Rosivall L, Navar LG (1983) Effects on renal hemodynamics of intra-arterial infusions of angiotensins I and II. Am J Physiol 245:F181–F187
Liu FY, Cogan MG (1988) Angiotensin II stimulation of hydrogen ion secretion in the rat early proximal tubule: modes of action, mechanism, and kinetics. J Clin Invest 82:601–607
Garvi JL (1991) Angiotensin stimulates bicarbonate transport and Na+/K+ ATPase in rat proximal straight tubules. J Am Soc Nephrol 1:1146–1152
Mitchell KD, Braam B, Navar LG (1992) Hypertensinogenic mechanisms mediated by renal actions of renin–angiotensin system. Hypertension 19:118–127
Eiam-Ong S, Hilden SA, Johns CA, Madias NE (1993) Stimulation of basolateral Na+–HCO3− cotransporter by angiotensin II in rabbit renal cortex. Am J Physiol 265:F195–F203
Wang T, Giebisch G (1996) Effects of angiotensin II on electrolyte transport in the early and late distal tubule in rat kidney. Am J Physiol 271:F143–F149
Stanton A, Jensen C, Nussberger J, O’Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137–1143
McMurray JJC, Pitt B, Latine R, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators et al (2008) Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17–24
Wood JM, Schnell CR, Cumin F, Menard J, Webb RL (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 23:417–426
Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243–256
Koka V, Huang XR, Chung ACK, Wang W, Truong LD, Lan HY (2008) Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol 175:1174–1183
Sullivan JC, Bhatia K, Yamamoto T, Elmarakby AA (2010) Angiotensin (1–7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension 56:658–666
Acknowledgments
This study was supported partially by a Research Grant obtained from All India Council for Technical Education, New Delhi (File no. 8023/BOR/RID/RPS-167/2007–2008). This paper is dedicated to the fond memories of Prof. Manjeet Singh who expired on 30-03-2009 while this study was in progress. We wish to express our gratitude to Sanofi-Aventis, Germany and Novartis; USA for providing AVE0991 and ALK as an ex-gratia, respectively. We also wish to our sincere thank to the management of ISF college of pharmacy for providing research facility.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Singh, Y., Singh, K. & Sharma, P.L. Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA–salt-induced hypertension in rats. Mol Cell Biochem 373, 189–194 (2013). https://doi.org/10.1007/s11010-012-1489-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-012-1489-2